Before reconstitution:
After reconstitution: Use Esperoct® within 4 hours when stored up to 86 °F or within 24 hours when stored in the refrigerator.1
Esperoct® has the broadest storage temperature of ALL EHL products and compact packaging for easy storage.1-5
Ready when your patients are
Esperoct® is ready in 3 simple steps: Attach, Twist, and Mix. Your patients can infuse over 2 minutes.1
Please note: these are not the complete Esperoct® Instructions for Use. Please see the Instructions for Use provided with the Prescribing Information.
5 vial sizes for personalized treatment
Individualize prophylactic dosing frequency1 for your patients based on bleeding episodes. Esperoct® is an extended half-life (EHL) rFVIII with multiple vial sizes to choose from.
One proven starting dose for adults & adolescents
One proven starting dose for children
Help your patients navigate coverage
NovoCare® offers cost savings and support programs for your eligible patients with bleeding disorders.
Order Esperoct® for your patients
Order Esperoct® by phone, through an authorized trading partner, or by contacting your local Novo Nordisk representative.
Selected Important Safety Information for Esperoct®
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
Indications and Usage
Esperoct® [antihemophilic factor (recombinant), glycopegylated-exei] is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management of bleeding, and routine prophylaxis to reduce the frequency of bleeding episodes
- Esperoct® is not indicated for the treatment of von Willebrand disease
Important Safety Information
Contraindications
- Do not use in patients who have known hypersensitivity to Esperoct® or its components, including hamster proteins
Warnings and Precautions
- Hypersensitivity reactions, including anaphylaxis, may occur. Should hypersensitivity reactions occur, discontinue Esperoct® and administer appropriate treatment
- Development of neutralizing antibodies (inhibitors) has occurred. Perform an assay that measures Factor VIII inhibitor concentration if bleeding is not controlled with the recommended dose of Esperoct® or if the expected plasma Factor VIII activity levels are not attained
- Temporary decrease in Factor VIII incremental recovery (IR) has been observed after Esperoct® infusion, within the first 5 exposure days, in previously untreated patients (PUPs) <6 years of age. During the decreased IR period, these subjects may have an increased bleeding tendency. If bleeding is not controlled with the recommended dose of Esperoct® and/or the expected Factor VIII activity levels are not attained and Factor VIII inhibitors are not detected, consider adjusting the dose, dosing frequency, or discontinuing Esperoct®
Adverse Reactions
- The most frequently reported adverse reactions in clinical trials (≥1%) were rash, redness, itching (pruritus), and injection site reactions. Additional frequently reported adverse reactions (≥1%) in PUPs included Factor VIII inhibition and hypersensitivity.
Please click here for Esperoct® Prescribing Information.
- Esperoct® [package insert]. Plainsboro, NJ: Novo Nordisk Inc.
- Eloctate® [package insert]. Bioverativ Therapeutics Inc.; 2023.
- Adynovate® [package insert]. Lexington, MA: Baxalta US Inc.; 2023.
- Jivi® [package insert]. Whippany, NJ: Bayer HealthCare LLC; 2018.
- Altuviiio™ [package insert]. Waltham, MA: Bioverativ Therapeutics Inc.; 2023